Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder

被引：42
作者：
Czyzewski, Krzysztof [1 ]
Styczynski, Jan [1 ]
Krenska, Anna [1 ]
Debski, Robert [1 ]
Zajac-Spychala, Olga [2 ]
Wachowiak, Jacek [2 ]
Wysocki, Mariusz [1 ]
机构：
[1] Nicholas Copernicus Univ, Coll Med, Dept Pediat Hematol & Oncol, PL-85094 Bydgoszcz, Poland
[2] Poznan Univ Med Sci, Dept Oncol Hematol & Pediat Transplantol, Poznan, Poland
来源：
LEUKEMIA & LYMPHOMA | 2013年 / 54卷 / 03期
关键词：
Post-transplant lymphoproliferative disorder; Epstein-Barr virus; central nervous system; rituximab; EPSTEIN-BARR-VIRUS; ANTI-CD20 ANTIBODY RITUXIMAB; STEM-CELL TRANSPLANTATION; LYMPHOMA; CNS; LEUKEMIA; DISEASE;
D O I：
10.3109/10428194.2012.718342
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Post-transplant lymphoproliferative disorder (PTLD) caused by Epstein-Barr virus (EBV) is a severe complication in high-risk allogeneic hematopoietic stem cell transplant (HSCT) recipients. Central nervous system (CNS) involvement of PTLD is a very rare event in patients with HSCT. As no established standard therapy in CNS-EBV-PTLD is available, the aim of this study was analysis of the safety and efficacy of intrathecal rituximab therapy in a group of eight children and adolescents with CNS-EBV-PTLD. Seven patients responded to therapy: all clinical symptoms and EBV-DNA viral load resolved after a median 2 (range: 1-7) doses of rituximab. However, some magnetic resonance imaging (MRI) changes in brain scan persisted in two patients. In all patients, except one, no adverse events of the therapy were observed. In conclusion, intrathecal rituximab administration seems to be an effective and safe method of treatment of CNS-EBV-PTLD in pediatric stem cell recipients. We recommend this treatment modality for further investigation.
引用
收藏
页码：503 / 506
页数：4
相关论文
共 20 条
[1]   Primary central nervous system post-transplant lymphoproliferative disorder presenting as cerebral hemorrhage after unrelated bone marrow transplantation [J].
Aisa, Y. ;
Mori, T. ;
Nakazato, T. ;
Suzuki, S. ;
Suzuki, N. ;
Ikeda, Y. ;
Okamoto, S. .
TRANSPLANT INFECTIOUS DISEASE, 2009, 11 (05) :438-441
[2]   Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant [J].
Bonney, Denise K. ;
Htwe, Ei E. ;
Turner, Andrew ;
Kelsey, Anna ;
Shabani, Abdu ;
Hughes, Stephen ;
Hughes, Imelda ;
Wynn, Robert F. .
PEDIATRIC BLOOD & CANCER, 2012, 58 (03) :459-461
[3]   Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy [J].
Carlos Jaime-Perez, Jose ;
Rodriguez-Romo, Laura N. ;
Gonzalez-Llano, Oscar ;
Chapa-Rodriguez, Adrian ;
Gomez-Almaguer, David .
BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (05) :794-795
[4]   Primary Central Nervous System Post-Transplantation Lymphoproliferative Disorder An International Primary Central Nervous System Lymphoma Collaborative Group Report [J].
Cavaliere, Robert ;
Petroni, Gina ;
Lopes, Maria B. ;
Schiff, David .
CANCER, 2010, 116 (04) :863-870
[5]   Complement activation in circulation and central nervous system after Rituximab (Anti-CD20) treatment of B-Cell lymphoma [J].
Harjunpää, A ;
Wiklund, T ;
Collan, J ;
Janes, R ;
Rosenberg, J ;
Lee, D ;
Grillo-López, A ;
Meri, S .
LEUKEMIA & LYMPHOMA, 2001, 42 (04) :731-738
[6]  
Jahnke Kristoph, 2006, Neurosurg Focus, V21, pE11
[7]   Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges [J].
Kittan, N. A. ;
Beier, F. ;
Kurz, K. ;
Niller, H. H. ;
Egger, L. ;
Jilg, W. ;
Andreesen, R. ;
Holler, E. ;
Hildebrandt, G. C. .
TRANSPLANT INFECTIOUS DISEASE, 2011, 13 (05) :524-530
[8]   Successful Treatment of EBV PTLD with CNS Lymphomas with the Monoclonal Anti-CD20 Antibody Rituximab [J].
Kordelas, Lambros ;
Trenschel, Rudolf ;
Koldehoff, Michael ;
Elmaagacli, Ahmet ;
Beelen, Dietrich W. .
ONKOLOGIE, 2008, 31 (12) :691-693
[9]   Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab [J].
Liu, Chun-Yu ;
Teng, Hao-Wei ;
Lirng, Jiing-Feng ;
Chiou, Tzeon-Jye ;
Chen, Po-Min ;
Hsiao, Liang-Tsai .
LEUKEMIA & LYMPHOMA, 2008, 49 (10) :2018-2021
[10]   Clinical characteristics of patients with Epstein Barr virus in cerebrospinal fluid [J].
Martelius, Timi ;
Lappalainen, Maija ;
Palomaki, Maarit ;
Anttila, Veli-Jukka .
BMC INFECTIOUS DISEASES, 2011, 11
12